Discovery of Microbiome-based Biomarkers for Patients With Cancer Using Metagenomic Approach
NCT ID: NCT04567446
Last Updated: 2024-06-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1100 participants
OBSERVATIONAL
2018-01-22
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Utilization of Microbiome as Biomarkers and Therapeutics in Immuno-Oncology
NCT04264975
Characterisation of the Intratumoral Microbiome in Gastric Adenocarcinoma: to a Personalised Medicine
NCT05800236
Gut Microbiota Reconstruction for NSCLC Immunotherapy
NCT05008861
Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy
NCT04333004
Interaction Between Host, Microenvironment and Immunity on Gastrointestinal Neoplasms
NCT04363983
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with bladder cancer who will start cancer treatment
Collection of biological samples (stool and blood) and data from patients included in the study will be performed:
1. By identifying the patients who will start treatment anticancer (chemotherapy, hormone therapy, immunotherapy).
2. Collection of biological resources (all samples will be collected in fresh): stool and blood
3. Collection of clinical data corresponding to each patient included in the study by a clinical research assistant
Stool
collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
Blood sample
20 mL collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
Patients with Non-Small-Cell Lung cancer who will start cancer treatment
Collection of biological samples (stool and blood) and data from patients included in the study will be performed:
1. By identifying the patients who will start treatment anticancer (chemotherapy, hormone therapy, immunotherapy).
2. Collection of biological resources (all samples will be collected in fresh): stool and blood
3. Collection of clinical data corresponding to each patient included in the study by a clinical research assistant
Stool
collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
Blood sample
20 mL collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
Patients with kidney cancer who will start cancer treatment
Collection of biological samples (stool and blood) and data from patients included in the study will be performed:
1. By identifying the patients who will start treatment anticancer (chemotherapy, hormone therapy, immunotherapy).
2. Collection of biological resources (all samples will be collected in fresh): stool and blood
3. Collection of clinical data corresponding to each patient included in the study by a clinical research assistant
Stool
collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
Blood sample
20 mL collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Stool
collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
Blood sample
20 mL collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient information and signature of the consent form before any specific procedure for the study. The patient must be able and must be inclined to cooperate in the study procedures.
* Patient affiliated to a social security scheme or beneficiary of a similar scheme.
Exclusion Criteria
* Patient under guardianship or curatorship or deprived of liberty by a decision judicial or administrative or patient unable to give his consent.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gustave Roussy, Cancer Campus, Grand Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gustave Roussy
Villejuif, Val De Marne, France
Centre hospitalier du Pays d'Aix
Aix-en-Provence, , France
Centre Pierre Curie
Beuvry, , France
Clinique du Flandre
Coudekerque-Branche, , France
CHRU Lille - Hôpital Calmette
Lille, , France
Centre Léon Bérard
Lyon, , France
Hôpital St Louis
Paris, , France
Hôpital Foch
Suresnes, , France
Centre hospitalier TOULON - Sainte-Musse
Toulon, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017/2619
Identifier Type: OTHER
Identifier Source: secondary_id
2017-A02010-53
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.